LEXINGTON, Mass., Sept. 15, 2015 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (Nasdaq:TTOO), a company developing innovative diagnostic products to improve patient health, today announced that new data on the company's T2Candida® Panel will be presented at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) and the International Society of Chemotherapy (ICC) joint meeting in San Diego, September 17-21, 2015. The poster data demonstrates that T2Candida is more sensitive and rapid than blood culture at monitoring disease and treatment for invasive candidiasis in proven cases of candidemia infection.
The schedule for the ICAAC 2015 presentation is as follows:
|Title:||T2Candida is More Sensitive and Rapid than Blood Culture for Monitoring Invasive Candidiasis in Proven Cases of Infection|
|Date & Time:||Saturday, September 19, 2015, 11:00 a.m.-1:00 p.m.|
|Location:||Exhibit Hall F|
|Authors:||Peter Pappas, M.D., FACP, professor of medicine, division of infectious diseases, University of Alabama at Birmingham; principal investigator, Mycoses Study Group|
|Eleftherios Mylonakis, MD, PhD, FIDSA, Chief, Division of Infectious Diseases, Rhode Island Hospital and The Miriam Hospital and Dean's Professor of Medical Science Alpert Medical School at Brown University, Providence, RI.|
|M. Hong Nguyen, MD, Professor of Medicine, Director, Transplant Infectious Diseases, Director, Antimicrobial Management Program, University of Pittsburgh Medical Center (Presenter)|
T2 Biosystems will also sponsor a symposium, "You're Missing More than You Think: A Data-Driven Discussion on Identifying Invasive Infections in Culture Negative Patients," on Saturday, September 19, 2015, at 11:30 a.m. at the San Diego Convention Center – Meeting Room 6D. The event will be moderated by Michael Pfaller, M.D., chief medical officer of T2 Biosystems, and speakers include:
- Peter Pappas, M.D., FACP, professor of medicine, division of infectious diseases, University of Alabama at Birmingham; principal investigator, Mycoses Study Group
- Maiken Cavling Arendrup, Prof. M.D., Dr. Med SCI, Ph.D., head of mycology, Statens Serum Institut, Copenhagen, Denmark, chairman of the EUCAST-AFST, founder of the NSMM
The event is free to attend and lunch will served. Please register in advance online at http://info.t2biosystems.com/icaac2015.
Additionally, T2 Biosystems will host a presentation in its booth, which describes the outcomes and economic case for T2Candida that drove the adoption process at Lee Memorial Hospital System, as well as highlight specific patient cases where T2Candida may deliver the greatest cost and clinical benefit to the hospital system. The panel presentation details are as follows:
|Title:||Establishing T2Candida as a Standard of Care: A Hospital Case Study|
|Date & Time:||Friday, September 18, 2015, 1:30-2 p.m.|
|Saturday, September 19, 2:30-3 p.m.|
|Sunday, September 20, 12:30-1 p.m.|
|Presenter:||Sandy Estrada, Pharm.D., BCPS, pharmacy clinical specialist in infectious disease at Lee Memorial Health System, co-chair Antimicrobial Stewardship Committee, program director for the PGY-2 infectious diseases residency at Lee Memorial Health System|
About T2 Biosystems
T2 Biosystems is focused on developing innovative diagnostic products to improve patient health. With two FDA-cleared products targeting sepsis and a range of additional products in development, T2 Biosystems is an emerging leader in the field of in vitro diagnostics. The Company is utilizing its proprietary T2 Magnetic Resonance platform, or T2MR, to develop a broad set of applications aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. T2MR enables the fast and sensitive detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, eliminating the time-consuming sample prep required in current methods. For more information, please visit www.t2biosystems.com.
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the performance of the Company's diagnostic products and the ability to bring such products to market. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 4, 2015, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change. These forward-looking statements should not be relied upon as representing the Company's views as of any date subsequent to the date of this press release.
Source:T2 Biosystems, Inc.